Comparative Effectiveness in Pain-Related Outcomes and Health Care Utilizations between Veterans with Major Depressive Disorder Treated with Duloxetine and Other Antidepressants: A Retrospective Propensity Score-Matched Comparison

Pain Practice

Volumn 12, Issue 5, 2012, Pages 374-381

  Shi, Lizheng ^a,b,c   Liu, Jinan ^a,c   Zhao, Yang ^d  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressive agents; Health care utilization; Health related outcomes; Major depressive disorder; Opioid use

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; FLUOXETINE; MIRTAZAPINE; OPIATE; PAROXETINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; FIBROMYALGIA; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PAIN; PREVALENCE; PROPENSITY SCORE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; VETERAN;

EID: 84861931166     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00495.x     Document Type: Article

References (29)

1. Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry. 2008;20:209-218.
2. McIntyre RS, Konarski JZ. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. Expert Opin Pharmacother. 2005;6:707-713.
3. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436-1442.
4. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder [see comment]. J Psychiatr Res. 2005;39:43-53.
5. Stewart DE. Physical symptoms of depression: unmet needs in special populations. J Clin Psychiatry. 2003;64(suppl 7):12-16.
6. Fishbain DA. The association of chronic pain and suicide. Semin Clin Neuropsychiatry. 1999;4:221-227.
7. Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2009;113:263-271.
8. Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry. 2008;20:187-193.
9. Veterans Health Administration, Department of Defense. VHA/DOD Clinical Practice Guideline for the Management of Major Depressive Disorder in Adults, Vol. 2010. Washington, DC: Veterans Health Administration, Department of Defense; 2000.
10. Delgado PL. Common pathways of depression and pain. J Clin Psychiatry. 2004;65(suppl 12):16-19.
11. Perahia DGS, Quail D, Desaiah D, Montejo AL, Schatzberg AF. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res. 2009;43:512-518.
12. Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K. Impact of Pain on Depression Treatment Response in Primary Care. Psychosom Med. 2004;66:17-22.
13. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.[see comment]. J Clin Psychiatry. 2007;68:1707-1716.
14. Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(suppl 13):30-37.
15. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45:17-28.
16. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164:900-909.
17. Gayman MD, Brown RL, Cui M. Depressive symptoms and bodily pain: the role of physical disability and social stress. Stress Health. 2011;27:52-53.
18. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311:576-584.
19. U.S. Department of Health and Human Services. ICD-9-CM Official Guidelines for Coding and Reporting, Vol. 2010. Washington, DC: U.S. Department of Health and Human Services; 2008.
20. Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand. 2011;123:247-265.
21. Sussman N. SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms. Prim Care Companion J Clin Psychiatry. 2003;5:19-26.
22. McQuay H. Opioids in pain management. Lancet. 1999;353:2229-2232.
23. Rubin RR, Ma Y, Peyrot M, et al. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 2010;33:2549-2551.
24. Palos GR, Mendoza TR, Mobley GM, Cantor SB, Cleeland CS. Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain. 2006;7:49-56.
25. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440-449.
26. Shu H, Arita H, Hayashida M, et al. Anti-hypersensitivity effects of Shu-jing-huo-xue-tang, a Chinese herbal medicine, in CCI-neuropathic rats. J Ethnopharmacol. 2010;131:464-470.
27. Wise TN, Wiltse CG, Iosifescu DV, Sheridan M, Xu JY, Raskin J. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract. 2007;61:1283-1293.
28. Shi L, Liu J, Campbell C, Zhao Y. Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study. Curr Med Res Opin. 2010;26:2715-2721.
29. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.